Stock Price & Analysis

Based on the provided data and recent market activity, here's my analysis of whether to buy or sell ABT stock:

Technical Analysis: The stock shows strong bullish momentum, having risen 8.07% in the past month. Currently trading at $117.69, ABT has formed a solid uptrend with higher lows and higher highs. The stock is trading above both its 5-day ($132.20) and 200-day ($112.50) moving averages, indicating positive momentum.

Fundamental Strength:

• Forward P/E of 25.88x, trading at a premium to industry average of 20.03x
• Expected EPS growth of 10.28% for FY2025 with revenue projected to grow 5.73%
• Strong balance sheet with current ratio of 1.64 and healthy debt-to-equity metrics

Analyst Consensus: Among 25 analysts covering ABT:

• 17 Strong Buy
• 2 Moderate Buy
• 6 Hold The mean price target of $136.09 implies a 6.1% upside potential from current levels.

Growth Catalysts:

• Medical Devices division showing robust 12% revenue growth
• Promising outlook for Lingo continuous glucose monitoring system launched in September 2024
• Strong product portfolio across diagnostics, medical devices, nutrition and pharmaceuticals

Recommendation: BUY The combination of strong technical momentum, solid fundamentals, and positive analyst sentiment suggests ABT is well-positioned for continued growth. The stock offers an attractive entry point for long-term investors looking for exposure to the healthcare sector.

Based on the technical indicators and fundamental analysis, Abbott Laboratories (ABT) stock is projected to reach $150 by end of 2025, supported by strong earnings growth expectations of 10.1% and positive analyst sentiment with a "Strong Buy" consensus rating. The company's robust product portfolio and strategic positioning in the medical devices market, coupled with its current technical momentum showing RSI at 70.98 and trading above all major moving averages, suggests continued upward trajectory.

The S1 support level for ABT Stock is $129.28 ,The R1 resistant level for ABT Stock is $135.65.

As of the end of day on 2025-02-26, the price of ABT Stock was $135.02.

The target price for ABT Stock according to analyst rating is 137.43, with the highest price target at 158.00 and the lowest at 117.00. Analysts have a Strong Buy rating on ABT Stock overall.

The market cap of ABT is $235.6B.

Based on the provided data and recent market performance, here's a concise analysis of ABT's valuation:

ABT's current P/E ratio of 33.64x is significantly higher than its 2022 level of 27.93x, indicating potential overvaluation. The EV/EBITDA multiple has also expanded to 19.94x from 16.56x, suggesting premium pricing compared to historical levels.

The stock's recent price surge to $134.92 (+1.31%) places it well above both its 60-day SMA ($119.92) and 200-day SMA ($112.50), indicating overbought conditions in the near term. The RSI-14 reading of 70.98 further supports this view.

Revenue declined 8.1% in 2023 to $40.1B, while net income dropped 17.5% to $5.72B, showing deteriorating fundamentals. The net margin contracted to 14.27% from 15.88% year-over-year.

However, analysts maintain optimism with consensus estimates projecting 10.28% EPS growth to $5.15 in 2025. The mean price target of $136.09 suggests only modest 6.1% upside potential from current levels.

Given the elevated valuation multiples, declining fundamentals, and limited upside potential based on analyst targets, ABT appears overvalued at current price levels despite positive growth expectations.

Abbott Laboratories is a global healthcare company. The Company is engaged in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. The Diagnostic Products segment is engaged in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment is involved in the worldwide sales of a broad line of adult and pediatric nutritional products. The Medical Devices segment includes the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products.

Based on the available data and analyst perspectives, here's a projection for Abbott Laboratories (ABT) stock price in 2030:

Abbott's stock is expected to reach approximately $195-210 by 2030, driven by strong growth in its diabetes care and medical device segments. The company's continuous glucose monitoring systems and structural heart products are projected to maintain double-digit growth. Abbott's strategic focus on expanding market share in insulin-intensive patients and tapping into the consumer market with Lingo CGM will be key growth catalysts.

The projection is supported by Abbott's robust business model diversification across multiple healthcare segments, with Diabetes Care (14.36%), Core Laboratory (12.86%), and Adult Nutritionals (10.52%) leading revenue contributions. The company's consistent margin improvement initiatives and focus on operational efficiency position it well for sustained double-digit EPS growth through the decade.

ABT has a total of 114000 employees.